Literature DB >> 16193385

Alterations in p53, p21, and MIB-1 labeling index in primary human astrocytomas following radiation therapy.

John W Henson1, Wendy Hobbs, Arnab Chakravarti, David N Louis.   

Abstract

Little is known about the cellular and genetic changes that occur in human astrocytomas following radiation therapy (RT). Experimental studies would suggest that early effects include induction of p53 and p21 expression, cell cycle arrest, and selection of tumor cells with molecular changes that correlate with radiation resistance. Unfortunately, tissue sampling of primary human astrocytomas closely following radiation therapy is uncommon, hindering comparative assessment of primary human tumors. Through local databases, we were able to collect eight cases in which tissue was resected within 8 weeks of RT because of bulky residual disease: two patients with grade II diffuse astrocytomas (LGA) and 6 patients with high-grade astrocytomas (HGA; 1 anaplastic astrocytoma, 5 glioblastomas). Routine histopathologic sections, MIB-1 labeling index (LI), p53 and p21 expression, and EGFR expression were compared between the pre- and post-RT samples. Only one tumor (52d post-RT) showed prominent radiation-induced histopathologic changes. p53 expression was detected in two tumors pre-RT and in six tumors post-RT. In the four tumors in which p53 expression was induced, the post-RT LI was lower in each case, and p21 expression had increased in 3/4 of these cases. No change in LI was detected in tumors in which p53 expression was unchanged. EGFR expression was not altered following RT. The results of this unique series document that some primary human astrocytomas increase expression of p53 and p21 and decrease proliferation in response to RT. However, the small size of the series argues for further studies of radiation induced molecular changes in primary human astrocytoma tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16193385     DOI: 10.1007/s11060-004-6911-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  High dose radiation therapy in the treatment of malignant gliomas: final report.

Authors:  O M Salazar; P Rubin; M L Feldstein; R Pizzutiello
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-10       Impact factor: 7.038

2.  Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations.

Authors:  M Tada; R Matsumoto; R D Iggo; R Onimaru; H Shirato; Y Sawamura; Y Shinohe
Journal:  Cancer Res       Date:  1998-05-01       Impact factor: 12.701

Review 3.  Regulation of p53 in response to DNA damage.

Authors:  N D Lakin; S P Jackson
Journal:  Oncogene       Date:  1999-12-13       Impact factor: 9.867

Review 4.  Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.

Authors:  M Nozaki; M Tada; H Kobayashi; C L Zhang; Y Sawamura; H Abe; N Ishii; E G Van Meir
Journal:  Neuro Oncol       Date:  1999-04       Impact factor: 12.300

5.  Radiation response and survival time in patients with glioblastoma multiforme.

Authors:  F G Barker; M D Prados; S M Chang; P H Gutin; K R Lamborn; D A Larson; M K Malec; M W McDermott; P K Sneed; W M Wara; C B Wilson
Journal:  J Neurosurg       Date:  1996-03       Impact factor: 5.115

6.  Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor.

Authors:  M Rojas; S Yao; Y Z Lin
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

7.  High levels of p53 protein in UV-irradiated normal human skin.

Authors:  P A Hall; P H McKee; H D Menage; R Dover; D P Lane
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

8.  Comparative study of p53 gene and protein alterations in human astrocytic tumors.

Authors:  D N Louis; A von Deimling; R Y Chung; M P Rubio; J M Whaley; R H Eibl; H Ohgaki; O D Wiestler; A D Thor; B R Seizinger
Journal:  J Neuropathol Exp Neurol       Date:  1993-01       Impact factor: 3.685

9.  The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.

Authors:  Arnab Chakravarti; Abhijit Chakladar; Meaghan A Delaney; Douglas E Latham; Jay S Loeffler
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  Human gliomas with wild-type p53 express bcl-2.

Authors:  L M Alderson; R L Castleberg; G R Harsh; D N Louis; J W Henson
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

View more
  4 in total

1.  Genetic characterization of adult infratentorial gliomas.

Authors:  Tomoru Miwa; Yuichi Hirose; Hikaru Sasaki; Eiji Ikeda; Kazunari Yoshida; Takeshi Kawase
Journal:  J Neurooncol       Date:  2008-10-22       Impact factor: 4.130

2.  The genetic landscape of gliomas arising after therapeutic radiation.

Authors:  Giselle Y López; Jessica Van Ziffle; Courtney Onodera; James P Grenert; Iwei Yeh; Boris C Bastian; Jennifer Clarke; Nancy Ann Oberheim Bush; Jennie Taylor; Susan Chang; Nicholas Butowski; Anuradha Banerjee; Sabine Mueller; Cassie Kline; Joseph Torkildson; David Samuel; Aleli Siongco; Corey Raffel; Nalin Gupta; Sandeep Kunwar; Praveen Mummaneni; Manish Aghi; Philip Theodosopoulos; Mitchel Berger; Joanna J Phillips; Melike Pekmezci; Tarik Tihan; Andrew W Bollen; Arie Perry; David A Solomon
Journal:  Acta Neuropathol       Date:  2018-09-08       Impact factor: 15.887

3.  Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.

Authors:  Wei-Ying Yue; Ke Sai; Qiu-Liang Wu; Yun-Fei Xia; Su-Huan Yu; Zhong-Ping Chen
Journal:  Chin J Cancer       Date:  2012-02-07

4.  18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns.

Authors:  Sanjay Chandrasekaran; Andrew Hollander; Xiangsheng Xu; Joseph L Benci; James J Davis; Jay F Dorsey; Gary Kao
Journal:  ScientificWorldJournal       Date:  2013-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.